These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32658783)

  • 1. Pharmacophore-enabled virtual screening, molecular docking and molecular dynamics studies for identification of potent and selective histone deacetylase 8 inhibitors.
    Kashyap K; Kakkar R
    Comput Biol Med; 2020 Aug; 123():103850. PubMed ID: 32658783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
    Kashyap K; Kakkar R
    J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
    Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
    Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetically selective and potent inhibitors of HDAC8.
    Schweipert M; Jänsch N; Sugiarto WO; Meyer-Almes FJ
    Biol Chem; 2019 May; 400(6):733-743. PubMed ID: 30521473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery.
    Thangapandian S; John S; Lee Y; Kim S; Lee KW
    Int J Mol Sci; 2011; 12(12):9440-62. PubMed ID: 22272142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacophore-based virtual screening, 3D QSAR, Docking, ADMET, and MD simulation studies: An in silico perspective for the identification of new potential HDAC3 inhibitors.
    Lanka G; Begum D; Banerjee S; Adhikari N; P Y; Ghosh B
    Comput Biol Med; 2023 Nov; 166():107481. PubMed ID: 37741229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.
    Zhao C; Zang J; Ding Q; Inks ES; Xu W; Chou CJ; Zhang Y
    Eur J Med Chem; 2018 Apr; 150():282-291. PubMed ID: 29533873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of potent HDAC 2 inhibitors using E-pharmacophore modelling, structure-based virtual screening and molecular dynamic simulation.
    Pai P; Kumar A; Shetty MG; Kini SG; Krishna MB; Satyamoorthy K; Babitha KS
    J Mol Model; 2022 Apr; 28(5):119. PubMed ID: 35419753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design of selective HDAC2 inhibitors for liver cancer treatment: computational insights into the selectivity mechanism through molecular dynamics simulations and QM/MM calculations.
    Yang Y; Hu B; Yang Y; Gong K; Wang H; Guo Q; Tang X; Li Y; Wang J
    Phys Chem Chem Phys; 2021 Aug; 23(32):17576-17590. PubMed ID: 34369509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel hit compounds as potential HDAC1 inhibitors: The case of ligand- and structure-based virtual screening.
    Sirous H; Campiani G; Calderone V; Brogi S
    Comput Biol Med; 2021 Oct; 137():104808. PubMed ID: 34478925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
    Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
    J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel isoform-selective histone deacetylases 5 and 9 inhibitors through combined ligand-based pharmacophore modeling, molecular mocking, and molecular dynamics simulations for cancer treatment.
    Elmezayen AD; Al-Obaidi A; Yelekçi K
    J Mol Graph Model; 2021 Jul; 106():107937. PubMed ID: 34049193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8.
    Hou X; Du J; Liu R; Zhou Y; Li M; Xu W; Fang H
    J Chem Inf Model; 2015 Apr; 55(4):861-71. PubMed ID: 25757142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
    Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
    Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic-based cancer therapeutics: new potential HDAC8 inhibitors.
    Hassanzadeh M; Mahernia S; Caprini G; Fossati G; Adib M; Moakedi F; Amanlou M
    J Biomol Struct Dyn; 2022 Jan; 40(1):297-311. PubMed ID: 32886033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting.
    Hassan MM; Israelian J; Nawar N; Ganda G; Manaswiyoungkul P; Raouf YS; Armstrong D; Sedighi A; Olaoye OO; Erdogan F; Cabral AD; Angeles F; Altintas R; de Araujo ED; Gunning PT
    J Med Chem; 2020 Aug; 63(15):8634-8648. PubMed ID: 32672458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing.
    Liu J; Zhu Y; He Y; Zhu H; Gao Y; Li Z; Zhu J; Sun X; Fang F; Wen H; Li W
    J Biomol Struct Dyn; 2020 Feb; 38(2):533-547. PubMed ID: 30938574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QSAR modeling to design selective histone deacetylase 8 (HDAC8) inhibitors.
    Cao GP; Thangapandian S; Son M; Kumar R; Choi YJ; Kim Y; Kwon YJ; Kim HH; Suh JK; Lee KW
    Arch Pharm Res; 2016 Oct; 39(10):1356-1369. PubMed ID: 27542119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative quantitative structural assessment of benzothiazine-derived HDAC8 inhibitors by predictive ligand-based drug designing approaches.
    Banerjee S; Baidya SK; Adhikari N; Jha T
    SAR QSAR Environ Res; 2022 Dec; 33(12):987-1011. PubMed ID: 36533308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the potential binding sites of some known HDAC inhibitors on some HDAC8 conformers by docking studies.
    Sixto-López Y; Gómez-Vidal JA; Correa-Basurto J
    Appl Biochem Biotechnol; 2014 Aug; 173(7):1907-26. PubMed ID: 24888409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.